# Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mut

Source: https://onco.cc/trials/nct06784791/  
OnCo record `nct06784791` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of carboplatin and pemetrexed in lung cancer, run by University Hospital, Essen, now recruiting.

## Summary

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) is a phase 2, interventional study registered as NCT06784791 by University Hospital, Essen, with a registry enrolment figure of 20 participants, started 2024-11-06 and due to reach its primary completion in 2027-07-31. Interventions recorded: Amivantamab Intravenous; Carboplatin/Pemetrexed. Conditions listed: Lung Cancer (NSCLC). Primary outcome: Feasibility of one cycle of preoperative amivantamab therapy. Lung eligibility wording from the registry: ", bronchoscopy-guided biopsy) confirmed non-small-cell lung cancer (NSCLC) eligible for anatomic resection, with the following specifications:". Sites: Belgium, Germany, Netherlands. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: NEOpredict-EGF
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06784791
- Phase: 2
- Setting: Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
- Sponsor: University Hospital, Essen
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06784791: https://clinicaltrials.gov/study/NCT06784791

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06784791.json